Constance C. McDaniel Medically Necessary Infant Formula and Donor Milk Act
Summary
HR9007 is an early-stage bill authorizing a pilot program for infant formula financial assistance, but no funding amount is specified and it has only been referred to committee. No direct market impact is identifiable at this stage.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR9007 is in early legislative stage with no funding specified
- 2.No direct impact on any publicly traded company
- 3.Authorization does not guarantee appropriation; actual money requires separate bill
Market Implications
No market implications at this stage. The bill has not moved beyond committee referral and contains no funding amount. Investors should monitor for committee hearings or markup, which would signal potential progress.
Full Analysis
- On May 21, 2026, Rep. Wasserman Schultz (D-FL) introduced HR9007, the Constance C. McDaniel Medically Necessary Infant Formula and Donor Milk Act, which was referred to the House Committee on Energy and Commerce. The bill is in the earliest legislative stage with only one cosponsor and no further action. 2) The bill authorizes a 3-year pilot program to provide financial assistance for infant formula or donor milk to eligible individuals, but does not specify any dollar amount. Authorization is not appropriation; actual funding would require a separate appropriations bill. 3) No specific companies are named or directly affected. The program would likely involve government administration rather than direct contracts to formula manufacturers. 4) No real market data is provided for infant formula companies. The sector includes $REED (Reed's), $DAN (Darling Ingredients, which produces dairy ingredients), and $GIS (General Mills, which owns organic formula brands), but the bill's impact on any of these is negligible given the early stage and lack of funding. 5) The bill must pass committee, then the House, then the Senate, then be signed into law. With only one cosponsor and no companion bill in the Senate, passage in the 119th Congress is uncertain.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Protect Infant Formula from Contamination Act
Medium Transit Intensive Cities Authorization Act of 2026
To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to revise certain regulations related to infant and toddler beverages, and for other purposes.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.